Provided by Tiger Trade Technology Pte. Ltd.

Nektar Therapeutics

71.75
+0.37000.52%
Post-market: 71.750.00000.00%16:15 EDT
Volume:300.71K
Turnover:21.60M
Market Cap:2.45B
PE:-11.09
High:72.73
Open:70.41
Low:70.00
Close:71.38
52wk High:109.00
52wk Low:27.87
Shares:34.14M
Float Shares:28.53M
Volume Ratio:0.69
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4680
EPS(LYR):-9.7254
ROE:-35.75%
ROA:-12.54%
PB:2.71
PE(LYR):-7.38

Loading ...

BUZZ-Nektar starts $250 mln stock offering after alopecia treatment trial

Reuters
·
Apr 21

BRIEF-Nektar Therapeutics Announces Proposed Public Offering

Reuters
·
Apr 21

Nektar Therapeutics launches underwritten public offering of $250 million common stock

Reuters
·
Apr 21

Nektar Therapeutics - to Use Net Proceeds for R&D, Clinical Development, and General Corporate Purposes

THOMSON REUTERS
·
Apr 21

Nektar Therapeutics - Commences $250 Mln Underwritten Public Offering of Common Stock

THOMSON REUTERS
·
Apr 21

BUZZ-U.S. STOCKS ON THE MOVE-Adobe, Agios, QXO

Reuters
·
Apr 20

Wedbush Lifts Price Target on Nektar Therapeutics to $95 From $70, Maintains Neutral Rating

MT Newswires Live
·
Apr 20

Nektar rises 19.4%

TIPRANKS
·
Apr 20

Nektar Therapeutics Is Maintained at Buy by BTIG

Dow Jones
·
Apr 20

Nektar Therapeutics : Btig Raises Target Price to $178 From $151

THOMSON REUTERS
·
Apr 20

Nektar Therapeutics : H.c. Wainwright Raises Target Price to $185 From $165

THOMSON REUTERS
·
Apr 20

Nektar Therapeutics, Compass Pathways, Sila Realty Trust And Other Big Stocks Moving Higher On Monday

Benzinga_recent_news
·
Apr 20

Nektar Therapeutics Says New Rezpegaldesleukin Data Shows 'Deepening of Response' in Alopecia

MT Newswires Live
·
Apr 20

BUZZ-U.S. STOCKS ON THE MOVE-TopBuild, MDA Space, Biogen

Reuters
·
Apr 20

Nektar Therapeutics Shares up 17.8% Premarket After Alopecia Treatment Shows Promise in Extension Study

THOMSON REUTERS
·
Apr 20

Nektar Says In-Development Treatment for Hair Loss Has Promise

Dow Jones
·
Apr 20

Nektar reports new results from Phase 2b REZOLVE-AA study

TIPRANKS
·
Apr 20

Nektar Therapeutics - 29% and 31% of Patients Achieve Salt Score ≤20 From Week 36 to Week 52

THOMSON REUTERS
·
Apr 20

Nektar Therapeutics - Rezpegaldesleukin to Advance Into Late-Stage Development for Alopecia Areata

THOMSON REUTERS
·
Apr 20

52-Week Topline Results From 16-Week Blinded Treatment Extension of Rezolve-Aa Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata With Rezpegaldesleukin

THOMSON REUTERS
·
Apr 20